SBI-0206965

Cat. No.:	HY-16966		
CAS No.:	1884220-36-3		
Molecular Formula:	$C_{21}H_{21}BrN_4O_5$		
Molecular Weight:	489.32		
Target:	ULK; Autophagy; Apoptosis		
Pathway:	Autophagy; Apoptosis		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month

®

MedChemExpress

SOLVENT & SOLUBILITY

0,	0,	DMSO : ≥ 100 mg/mL (204.37 mM) * "≥" means soluble, but saturation unknown.				
		Solvent Mass Concentration	1 mg	5 mg	10 mg	
		1 mM	2.0437 mL	10.2183 mL	20.4365 mL	
	5 mM	0.4087 mL	2.0437 mL	4.0873 mL		
	10 mM	0.2044 mL	1.0218 mL	2.0437 mL		
	Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (5.11 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (5.11 mM); Clear solution					

BIOLOGICAL ACTIVITY			
Description	SBI-0206965 is a potent, selective and cell permeable autophagy kinase ULK1 inhibitor with IC ₅₀ s of 108 nM for ULK1 kinase and 711 nM for the highly related kinase ULK2 ^[1] .		
IC ₅₀ & Target	ULK1 108 nM (IC ₅₀)	ULK2 711 nM (IC ₅₀)	
In Vitro	SBI-0206965 (5-20 μM; 24 hours) induces apoptosis of A498 and ACHN cells during starvation ^[1] . SBI-0206965 (5-20 μM; 24 hours) attenuates the phosphorylation of Ser108 of the AMPK β1 subunit and increases the levels of cleaved Caspase 8 and PARP, markers of apoptosis ^[1] .		

Product Data Sheet

Br

0

0

N

NH

О.

	MCE has not independer Apoptosis Analysis ^[1]	ntly confirmed the accuracy of these methods. They are for reference only.		
	Cell Line:	A498 and ACHN cells (starvation medium (EBSS) treatment)		
	Concentration:	5, 10 ,20 μΜ		
	Incubation Time:	24 hours		
	Result:	Induced significant levels of apoptosis.		
	Western Blot Analysis ^[1]			
	Cell Line:	A498 and ACHN cells (EBSS treatment)		
	Concentration:	5, 10, 20 μM		
	Incubation Time:	24 hours		
	Result:	Attenuated the phosphorylation of Ser108 of the AMPK β1 subunit and increased the levels of cleaved Caspase 8 and PARP, markers of apoptosis. Autophagy was evaluated by analysis of LC3B and p62.		
In Vivo	tumours ^[1] .	SBI-0206965 (50 mg/kg; i.p.; once every 3 days for 37 days) inhibites tumour growth and induces apoptosis in A498 xenograft tumours ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.		
	Animal Model:	Six-week-old male BALB/c nude mice (A498 xenograft tumours) ^[1]		
	Dosage:	50 mg/kg		
	Administration:	Intraperitoneal injection; once every three days for 37 days		
	Result:	Significantly suppressed tumour growth.		

CUSTOMER VALIDATION

- Nature. 2016 Dec 1;540(7631):119-123.
- Autophagy. 2021 Feb;17(2):457-475.
- BioMedicine. 2018 Aug;34:85-93.
- Int J Biol Sci. 2021 Jul 5;17(11):2772-2794.
- Cell Rep. 2021 Jul 20;36(3):109398.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Lu J, et al. Overexpression of ULK1 Represents a Potential Diagnostic Marker for Clear Cell RenalCarcinoma and the Antitumor Effects of SBI-0206965. EBioMedicine. 2018 Aug;34:85-93.

[2]. Egan DF, et al. Small Molecule Inhibition of the Autophagy Kinase ULK1 and Identification of ULK1 Substrates. Mol Cell. 2015 Jul 16;59(2):285-97.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA